PDGFRB and pancreatic adenocarcinoma: Awasthi et al. studied the use of nintedanib, which is an angiokinase inhibitor of VEGFR1–3, fibroblast growth factor receptor 1–3, and platelet-derived growth factor receptor (PDGFR) α/β, in human pancreatic adenocarcinoma cell lines, such as AsPC-1 and BxPC-3, and in vivo in nu/nu mice.